Dulfaz Retard

Dalfaz Retard: an effective remedy for the treatment of prostate diseases

Dalfaz Retard is a medicinal product developed for the symptomatic treatment of dysuria associated with benign prostatic hyperplasia. It belongs to the pharmacological group of drugs intended for the treatment and prevention of prostate diseases. The drug is manufactured in France by Sanofi Winthrop Industrie.

Dalfaz Retard contains the active substance alfuzosin. It is available in the form of extended-release film-coated tablets with a dosage of 5 mg. This form ensures a gradual release of the active substance in the body, ensuring a long-lasting effect of the drug.

Indications for the use of Dalfaz Retard include symptoms of dysuria, both irritative and obstructive, caused by benign prostatic hyperplasia. This drug may be especially useful in cases where surgery is not possible or the disease progresses rapidly in older patients.

However, there are contraindications to the use of Dalfaz Retard. It is not recommended in patients with hypersensitivity to alfuzosin or in the patient's medical history of orthostatic hypotension. Also, you should not take Dalfaz Retard simultaneously with other alpha-blockers.

Like any medicine, Dalfaz Retard can cause side effects. Some of them include headache, dizziness, tinnitus, weakness, drowsiness, asthenia, orthostatic hypotension, tachycardia, exacerbation of angina symptoms in patients with coronary heart disease, dry mouth, nausea, epigastric pain, diarrhea, edema, redness of the skin , skin rashes and itching.

When using Dalfaz Retard, you should be careful about interactions with other medications. Concomitant use of alfuzosin with calcium channel blockers may increase the risk of developing hypertension, including orthostatic hypertension and collapse. It is also possible to develop blood pressure instability with simultaneous use of Dalfaz Retard with drugs for general anesthesia. However, no clinically significant vlix effects have been reported between Dalfaz Retard and other drugs.

The dosage of Dalphase Retard should be individually selected by the doctor, based on the characteristics of the patient and the characteristics of the disease. Usually recommended